20 results about "Subtilisins" patented technology

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents such as small interfering RNA (siRNA) molecules, able to inhibit proprotein convertase subtilisin kexin 9 (PCSK9) gene expression. Also disclosed are pharmaceutical compositions that include PCSK9 RNAi agents and methods of use thereof. The PCSK9 RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the delivery to hepatocyte cells. Delivery of the PCSK9 RNAi agents in vivo provides for in vivo provides for inhibition of PCSK9 gene expression and thereby reduction of PCSK9 protein. The RNAi agents can be used in methods of treatment of diseases or disorders mediated at least in part by PCSK9 gene expression, including among others hypercholesterolemia, familial hypercholesterolemia including heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH), familial hypobetalipoproteinemia, hyperlipidemia, coronary artery disease, polygenic dyslipidemia, heart disease, cardiovascular disease (CVD) including clinical atherosclerotic cardiovascular disease (ASCVD).

The present disclosure relates to small molecule inhibitors of proprotein convertase subtilisin-like / kexin type 9 (PCSK9), pharmaceutical compositions comprising said compounds, and their use in the prevention and treatment of diseases and disorders associated with PCSK9.

The invention belongs to the technical field of cosmetics, and provides a preparation method of a piper nigrum root extract and application of the piper nigrum root extract in pain relieving cosmetics. The kava pepper root extract is prepared by the following steps: crushing kava pepper roots, and performing alcohol extraction; carrying out secondary extraction by using a small molecular polyol solution containing isopropyl acetate; combining the extracting solutions, and adding compound enzymes (cellulase, pectinase and subtilisin) for enzymolysis to obtain a crude extract; and finally, carrying out subcritical extraction and purification on the crude extract to obtain the product. Through improvement of extraction and purification processes, the extraction rate of active ingredients is effectively increased, a certain amount of glutathione is obtained, and toxicity is reduced; the invention also discovers that the composition ratio of the active ingredients of the extract obtained by the optimized process is in a proper range, and the anti-inflammatory and analgesic effects of the Kava pepper root extract are further improved.

The present invention relates to a subtilisin BPN'variant or a homolog thereof comprising a new mutation compared to a subtilisin BPN 'as shown in SEQ ID NO: 3 or a homologous sequence thereof. This mutation may occur at an amino acid position selected from the group consisting of H17W, S18K, N25G, V30I, S63G, T71V, V72I, S204N, E251L, N43K or S87D.

Compositions and methods relating to ApoA-1 fusion polypeptides are disclosed. The fusion polypeptides include a first polypeptide segment corresponding to an ApoA-1 polypeptide or ApoA-1 mimetic, and may also include a dimerizing domain such as, e.g., an Fc region, which is typically linked carboxyl-terminal to the first polypeptide segment via a flexible linker. In some embodiments, the fusion polypeptide further includes a second polypeptide segment located carboxyl-terminal to the first polypeptide segment and which confers a second biological activity (e.g., an RNase, paraoxonase, platelet-activating factor acetylhydrolase, cholesterol ester transfer protein, lecithin-cholesterol acyltransferase, polypeptide that specifically binds to proprotein convertase subtilisin / kexin type 9, or polypeptide that specifically binds to amyloid beta). Also disclosed are dimeric proteins comprising first and second ApoA-1 fusion polypeptides as disclosed herein. The fusion polypeptides and dimeric proteins are useful in methods for therapy.

The invention discloses an active protease composition for expelling toxins and purifying skin, and relates to the technical field of protease compositions, the composition comprises the following components: a cross-source protease system composed of plant-source protease and microbial-source protease, the mass ratio of the plant-source protease to the microbial-source protease is 1: 0.5-1.5, and the mass ratio of the plant-source protease to the microbial-source protease is 1: 0.5-1.5; the papain and the subtilisin are precisely proportioned, so that protein in aged cutin can be decomposed, various impurities and toxins can be degraded, the range of decomposition substrates can be expanded, the impurities and toxins on skin can be removed, the pH value of a system can be adjusted by utilizing the grape seed extract and the green tea extract in the functional auxiliary agent, free radicals can be removed, and the skin quality can be improved. The active stability of protease is improved, it is guaranteed that the product can effectively play a role in different environments, by means of the anti-oxidation, anti-inflammatory and chelating functions of the functional auxiliary agent, skin inflammation damage is synchronously repaired in the detoxification and purification process, environmental oxidation damage is resisted, and all-around nursing is provided for skin.

The present invention provides variant subtilisins and compositions comprising at least one variant subtilisin set forth herein, as well as methods for using these variants and compositions. In some embodiments, the present invention provides variant subtilisins suitable for laundry cleaning applications.

Disclosed are, inter alia, double stranded RNAi (dsRNAi) agents inhibiting expression of proprotein convertase subtilisin kexin 9 (PCSK9), for example, human PCSK9, compositions including the same, and methods of treatment using the same.

Disclosed herein are one or more subtilisin variants, nucleic acids encoding the same, and compositions and methods related to production and use thereof, the one or more subtilisin variants include one or more subtilisin variants having improved stability and / or soil removability as compared to one or more reference subtilisins.

Fabric and home care compositions including a surfactant and a protease. The automatic dishwashing composition is in the form of a water-soluble unit-dose pouch including a compartment. The compartment includes both a powder component and a gel component. The protease is a subtilisin variant that includes: (i) a mutation at position 122; and (ii) one or more mutations at positions 126, 127, 128, 211 and 212, with reference to SEQ ID NO: 1. The variant has at least about 80% identity to the amino acid sequence of SEQ ID NO: 1.

An siRNA which inhibits proprotein convertase subtilisin / kexin type 9 (PCSK9) gene expression, a pharmaceutical composition containing the siRNA, and a conjugate. Each nucleotide in the siRNA is independently a modified or unmodified nucleotide. The siRNA contains a sense strand and an antisense strand. The sense strand contains nucleotide sequence I; nucleotide sequence I having the same length as the nucleotide sequence shown in SEQ ID NO: 1, with no more than three nucleotides differences. The antisense strand contains nucleotide sequence II, nucleotide sequence II having the same length as the nucleotide sequence shown in SEQ ID NO: 2, with no more than three nucleotides differences. The siRNA, pharmaceutical composition thereof and the conjugate can effectively treat and / or prevent hypercholesterolemia.

The present invention provides variant subtilisins and compositions comprising at least one variant subtilisin set forth herein, as well as methods for using these variants and compositions. In some embodiments, the present invention provides variant subtilisins suitable for laundry cleaning applications.

Disclosed are, inter alia, combinations comprising a first antisense (e.g., first double stranded RNAi (dsRNAi)) agent for inhibiting expression of proprotein convertase subtilisin kexin 9 (PCSK9), for example, human PCSK9, and a second antisense agent (e.g., second dsRNAi agent) for inhibiting expression of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR); pharmaceutical compositions including the same, and methods of treatment using the same.

Disclosed herein is one or more subtilisin variant, nucleic acid encoding same, and compositions and methods related to the production and use thereof, including one or more subtilisin variant that has improved stability and / or soil removal compared to one or more reference subtilisin.

The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin / Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.

Disclosed are, inter alia, double stranded RNAi (dsRNAi) agents inhibiting expression of proprotein convertase subtilisin kexin 9 (PCSK9), for example, human PCSK9, compositions including the same, and methods of treatment using the same.

The invention provides a pharmaceutical composition for resisting inflammation and repairing oral ulcer and a preparation method thereof, and belongs to the technical field of biological pharmacy, and the pharmaceutical composition comprises ciona glabra peptide, a cucurbita pepo seed extract, carboxymethylation modified hemerocallis citrina root polysaccharide, honeysuckle chlorogenic acid, baicalin and dipotassium glycyrrhizinate. The ciona ciona peptide is prepared by carrying out step-by-step enzymolysis on ciona ciona through trypsin and lumbrukinase and purifying through a sephadex G-15 column. The cucurbita pepo seed extract is prepared by breaking walls of cucurbita pepo seeds with a compound enzyme, performing enzymolysis with ficin protease and subtilisin, and purifying with a polyamide resin column. The carboxymethylation modified hemerocallis citrina root polysaccharide is prepared by alkalization and chloroacetic acid modification of hemerocallis citrina root extracted polysaccharide. All the components are compounded for use, so that multiple effects of resisting inflammation, easing pain and promoting epithelial cell proliferation and mucosal barrier repair are synergistically realized, and the treatment effect of oral ulcer is optimized.

The invention belongs to the technical field of medicines and skin care products, and particularly relates to application of a proprotein convertase subtilisin / kexin9 type (PCSK9) inhibitor in anti-aging and tissue repair products. The PCSK9 gene is characterized in that the PCSK9 belongs to a proprotein converting enzyme family. The PCSK9 inhibitor is a PCSK9 small molecule compound inhibitor, a PCSK9 monoclonal antibody, a PCSK9 small interfering RNA (Ribonucleic Acid), a PCSK9 mimic peptide inhibitor, a PCSK9 mimic antibody protein, a PCSK9 antisense oligonucleotide or a PCSK9 vaccine, and is applied to preparation of anti-aging and tissue repair products. A systematic or external PCSK9 inhibitor product can be further developed and is used for resisting aging and repairing tissues.

The present invention provides variant subtilisins and compositions comprising at least one variant subtilisin set forth herein, as well as methods for using these variants and compositions. In some embodiments, the present invention provides variant subtilisins suitable for laundry cleaning applications.

This invention discloses a formulation for pet oral cleaning and softening of dental plaque and tartar, and its preparation method, belonging to the technical field of pet oral cleaning formulations. The formulation comprises the following components: 0.5%-2.0% complex protease, 0.3%-1.2% repair agent, 0.05%-0.2% antibacterial agent, 0.2%-0.8% probiotic active liquid, 0.03%-0.3% metal chelating agent, 0.1%-2% emulsifier, 5%-15% humectant, 0.01%-0.3% breath freshener, 0.1%-0.5% pH adjuster, and the balance purified water. The complex protease is composed of subtilisin, bromelain, and papain. This invention, through the combination of a multi-enzyme synergistic system and active components, achieves effective removal of pet dental plaque and a significant softening and peeling effect on dental tartar. The resulting formulation is compatible with the pet's oral physiological environment, and long-term use can effectively prevent the occurrence of oral diseases.